Following a full submission
duloxetine (Cymbalta) is accepted for restricted use for the treatment of diabetic peripheral neuropathic pain in adults.
Duloxetine relieved peripheral neuropathic pain compared with placebo in patients with diabetes. It is restricted to initiation by prescribers experienced in the management of diabetic peripheral neuropathic pain as 2nd or 3rd line therapy.
Download detailed advice48KB (PDF)
- Medicine name:
- duloxetine 30mg and 60mg capsules (Cymbalta)
- SMC ID:
- Diabetic peripheral neuropathic pain in adults
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 11 September 2006